Multiple sclerosis: current knowledge and future outlook
CP Kamm, BM Uitdehaag, CH Polman - European neurology, 2014 - karger.com
Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous
system characterized by demyelination and axonal loss. The etiology of MS is unknown; …
system characterized by demyelination and axonal loss. The etiology of MS is unknown; …
Current disease‐modifying treatment of multiple sclerosis
J Derwenskus - Mount Sinai Journal of Medicine: A Journal of …, 2011 - Wiley Online Library
The treatment era for multiple sclerosis began in 1993 with the approval of the first disease‐
modifying therapy. This changed the management of multiple sclerosis from treating acute …
modifying therapy. This changed the management of multiple sclerosis from treating acute …
New management algorithms in multiple sclerosis
PS Sorensen - Current opinion in neurology, 2014 - journals.lww.com
In de novo-treated patients, the injectables, IFN-β and glatiramer acetate, will to a great
extent be replaced by the new orals, dimethyl fumarate and teriflunomide. However, patients …
extent be replaced by the new orals, dimethyl fumarate and teriflunomide. However, patients …
History of modern multiple sclerosis therapy
F Lublin - Journal of neurology, 2005 - Springer
Although the earliest recorded description of multiple sclerosis (MS) dates back to the 14 th
century, it was not until the latter years of the 20 th that treatments for this disabling condition …
century, it was not until the latter years of the 20 th that treatments for this disabling condition …
Multiple sclerosis: new insights and trends
M Inglese - American journal of neuroradiology, 2006 - Am Soc Neuroradiology
The past few years have witnessed major advancements in our ability to diagnose multiple
sclerosis (MS) and begin treatments that can favorably modify the course of the disease. In …
sclerosis (MS) and begin treatments that can favorably modify the course of the disease. In …
Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm
BAC Cree, J Mares, HP Hartung - Current opinion in neurology, 2019 - journals.lww.com
Current therapeutic landscape in multiple sclerosis: an evol... : Current Opinion in
Neurology Current therapeutic landscape in multiple sclerosis: an evolving treatment …
Neurology Current therapeutic landscape in multiple sclerosis: an evolving treatment …
[HTML][HTML] Treatment strategies for multiple sclerosis: when to start, when to change, when to stop?
A Gajofatto, MD Benedetti - World Journal of Clinical Cases: WJCC, 2015 - ncbi.nlm.nih.gov
Multiple sclerosis (MS) is a chronic inflammatory condition of the central nervous system
determined by a presumed autoimmune process mainly directed against myelin …
determined by a presumed autoimmune process mainly directed against myelin …
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies
DM Wingerchuk, JL Carter - Mayo Clinic Proceedings, 2014 - Elsevier
Multiple sclerosis (MS) is a chronic inflammatory demyelinating central nervous system
disease that typically strikes young adults, especially women. The pathobiology of MS …
disease that typically strikes young adults, especially women. The pathobiology of MS …
Treatment of multiple sclerosis—success from bench to bedside
M Tintore, A Vidal-Jordana… - Nature Reviews …, 2019 - nature.com
The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …
Symptomatic treatment and management of multiple sclerosis
The range of symptoms which occur in multiple sclerosis (MS) can have disabling functional
consequences for patients and lead to significant reductions in their quality of life. MS …
consequences for patients and lead to significant reductions in their quality of life. MS …